Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel group of hypolipidemic drugs that are recommended particularly for high-risk hypercholesterolemia patients, including those with primary hypercholesterolemia (PH), where lifelong exposure to high low-density lipoprotein (LD...

Descripción completa

Detalles Bibliográficos
Autores principales: Pęczek, Piotr, Leśniewski, Mateusz, Mazurek, Tomasz, Szarpak, Lukasz, Filipiak, Krzysztof J., Gąsecka, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224623/
https://www.ncbi.nlm.nih.gov/pubmed/34071103
http://dx.doi.org/10.3390/life11060466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224623/
https://www.ncbi.nlm.nih.gov/pubmed/34071103
http://dx.doi.org/10.3390/life11060466

Ejemplares similares